Safety assessment of inhaled xylitol in subjects with cystic fibrosis

Lakshmi Durairaj; Janice Launspach; Janet L Watt; Zeinab Mohamad; Joel Kline; Joseph Zabner

doi:10.1016/j.jcf.2006.05.002

Back

Safety assessment of inhaled xylitol in subjects with cystic fibrosis

Journal article

Open access

Peer reviewed

Safety assessment of inhaled xylitol in subjects with cystic fibrosis

Lakshmi Durairaj, Janice Launspach, Janet L Watt, Zeinab Mohamad, Joel Kline and Joseph Zabner

Journal of cystic fibrosis, Vol.6(1), pp.31-34

01/2007

DOI: 10.1016/j.jcf.2006.05.002

PMID: 16781897

Files and links (1)

url

https://doi.org/10.1016/j.jcf.2006.05.002View

Published (Version of record) Open Access

Abstract

Xylitol is a 5-carbon sugar that can lower the airway surface salt concentration, thus enhancing innate immunity. We tested the safety and tolerability of aerosolized iso-osmotic xylitol in subjects with cystic fibrosis. In this pilot study, 6 subjects with cystic fibrosis and an FEV1>60% predicted underwent a baseline spirometry followed by exposures to aerosolized saline (10 ml) and 5% xylitol (10 ml). Serum osmolarity and electrolytes were measured at baseline and after xylitol exposure. Spirometry, oxygen saturation and respiratory symptom questionnaire using visual analog scale were tested at baseline and after each exposure. Sputum for cytokine analysis was collected after saline and xylitol nebulizations. There was no change in FEV1 after xylitol exposure compared with baseline or normal saline exposure (p=0.19). Laboratory values and respiratory symptoms were not affected by xylitol inhalation. The mean IL-8 level in the sputum was similar with saline and xylitol exposures (3.5+/-0.5 vs. 3.5+/-0.6 ng/ml). A single dose inhalation of aerosolized iso-osmotic xylitol was well tolerated by subjects with cystic fibrosis. Future studies of long term safety are required.

Adjuvants, Immunologic - administration & dosage

Immunity, Innate - drug effects

Humans

Administration, Inhalation

Male

Interleukin-8 - analysis

Xylitol - adverse effects

Adjuvants, Immunologic - adverse effects

Animals

Xylitol - administration & dosage

Adult

Female

Mice

Cystic Fibrosis - drug therapy

Details

Title: Subtitle: Safety assessment of inhaled xylitol in subjects with cystic fibrosis
Creators: Lakshmi Durairaj - Department of Medicine, Roy J. and Lucille A., Carver College of Medicine, USA
Janice Launspach
Janet L Watt
Zeinab Mohamad
Joel Kline
Joseph Zabner
Resource Type: Journal article
Publication Details: Journal of cystic fibrosis, Vol.6(1), pp.31-34
DOI: 10.1016/j.jcf.2006.05.002
PMID: 16781897
ISSN: 1569-1993
eISSN: 1873-5010
Grant note: RR00059 / NCRR NIH HHS HL61234-06 / NHLBI NIH HHS K23 HL071246-01A1 / NHLBI NIH HHS
Language: English
Date published: 01/2007
Academic Unit: Pulmonary, Critical Care, and Occupational Medicine; Occupational and Environmental Health; Internal Medicine
Record Identifier: 9984094543202771

Metrics

18 Record Views

20 Times Cited - Web of Science

See more details